Biomarkers and Therapeutic Targets for Melanoma
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 72
Special Issue Editor
Interests: tumor microenvironment; tumor metabolism; melanoma; breast; drug resistance; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Melanoma is the most aggressive skin tumor, and its incidence has rapidly increased in recent years. Prevention remains the first form of treatment for this malignancy, because during its early stages, melanoma is curable. Although great progress has been made in therapy, unfortunately, metastatic melanoma still has high mortality rates, partly due to the establishment of secondary drug resistance in many patients. Malignant melanoma is highly heterogeneous and substantially resistant to unselective treatments, such as chemotherapy. For this reason, the research aims to identify biomarkers (intra- and inter-tumor) as new therapeutic targets, also from the perspective of precision medicine. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- New biomarkers for melanoma treatments;
- Molecular and genetic modifications associated with drug resistance in melanoma;
- The involvement of melanoma tumor microenvironment in cancer progression and drug resistance;
- Novel therapeutic approaches in melanoma treatments;
- Omics technologies applied to melanoma;
- Metabolism reprogramming in melanoma.
We look forward to receiving your contributions.
Dr. Italia Falcone
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- tumor microenvironment
- tumor metabolism
- omics technologies
- precision medicine
- biomarkers
- melanoma treatment approaches
- drug resistance
